Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome
Direct Biologics Granted FDA Approval of Third IND Application for the use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy Extracellular vesicle product ExoFlo clinical trials… Read More »Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome